The Role of Genetic Polymorphism of Cytochrome P450 2E1 in Bladder Cancer in Korea / 한국역학회지

Although the association of genetic polymorphisms in glutathione S-transferase(GST) and N-acetyltransferase(NAT) with bladder cancer has been reported, limited numbers of studies have been indicated the association of CYP2E1 with bladder cancer, particularly in Asian population. A hospital based case-control study was conducted in South Korean, consisting of 232 histologically confirmed prevalent bladder cancer cases and 165 controls to evaluate the association between genetic polymorphisms of CYP2E1(RsaI) and development of bladder cancer. The frequency of CYP2E1(RsaI) c1/c1 genotype in bladder cancer cases was higher than in controls; 114 of 201(56.7%) vs. 62 of 146(42.5%). Men with CYP2E1(RsaI) c1/c1 genotype had increased risk of development of bladder cancer compared to men with at least one c2 allele(OR=1.7, 95% CI=1.1-2.7). The bladder cancer risk increased as the number of c1 allele increased(p for trend=0.005). The risk increased as the amount of smoking increased(p for trend=0.009). When data were analyzed for the interaction between smoking and CYP2E1 genetic polymorphisms, smokers with c1/c1 genotype have 2.5 greater risk in development of bladder cancer(95% CI=1.0-6.2) compared to nonsmokers with c2 allele(p for interaction=0.008). Our findings suggest that the interaction between genetic polymorphisms of CYP 2E1 (RsaI, c1/c1) and smoking may play an important role for development of bladder cancer among Koreans.

Bacillus Calmette-Guerin Instillation As A Prophylactic Treatment of Superficial Bladder Tumor / 대한비뇨기과학회지

A study was performed to determine the prophylactic efficacy of intravesical BCG instillation in 35 patients with recurrent (more than 3), multiple (more than 3) or large (more than 3cm.) superficial bladder tumors(stage Ta or T1). Of the patients 20 were treated with 6 weekly intravesical instillations of 120mg. Pasteur strain BCG after transurethral resection and 15 were followed conventionally. The recurrence rate was 16.2 per cent in the BCG group and 40.1 per cent in the controls during the first 3 months, and it was 39.6 and 92.6 per cent, respectively during l2 months (p<0.005, logrank),Recurrence per 100 patient-months were 5.13 and 11.68, respectively (p<0.00l,chi-square). One patient in the BCG group and 3 controls had recurrent tumors with progression in stage. We conclude from these observations that intravesical BCG instillation is effective in the prophylaxis of tumor recurrence in patients at high risk.